MDGL

The accelerated FDA approval of Rezdiffra in March 2024 was a transformative event for Madrigal. In Q1 2026, the company reported Rezdiffra net sales of $311.3 million, a 127% year-over-year growth, with over 42,250 patients on the treatment. Q2 2026 saw Rezdiffra net sales of $364.3 million, a 71% year-over-year growth, with over 49,000 patients, achieving nearly $1.3 billion in trailing-12-month net sales. As of October 5, 2026, the share price was $493.60, an 11.60% increase over the previous year, despite recent short-term declines. MDGL reached its all-time high of $615.00 on December 23, 2025. Analysts have given Madrigal a 'Moderate Buy' consensus rating, and the company has participated in several healthcare conferences. Madrigal expanded its MASH pipeline with six preclinical siRNA programs in February 2026, strengthened its intellectual property with three new resmetirom patents in July 2026, and acquired a global license for Ervogastat from Pfizer in January 2026.